17.03.2015 Celesio AG  DE000CLS1001

DGAP-News: Celesio AG: Celesio announces results for fiscal 2014


 
DGAP-News: Celesio AG / Key word(s): Final Results Celesio AG: Celesio announces results for fiscal 2014 17.03.2015 / 10:00 --------------------------------------------------------------------- Celesio announces results for fiscal 2014 - Guaranteed dividend amounting to 0.83 euro Stuttgart, 17 March 2015. Celesio generated group revenue of 22,325.9 million euro in fiscal 2014, which is up 4.3 per cent year-on-year. When adjusted for currency effects, revenue actually increased by 4.2 per cent. Market growth in Germany as well as in Brazil and the good revenue performance in the United Kingdom, in Austria and in Norway more than compensated the loss in revenue of the Irish wholesale business, which was consolidated until May 2013. Adjusted earnings before interest and taxes (EBIT) fell by 3.0 per cent from 423.6 million euro to 410.9 million euro. On an operational basis, in particular the very good performance in the United Kingdom and Norway as well as supportive developments in other countries could compensate for the unfavourable trends in Brazil and France. EBIT was impacted by one-off effects in Brazil and Portugal. Performance in the divisions Revenue in the Consumer Solutions division - the pharmacy business - increased by 7.8 per cent from 3,411.9 million euro to 3,677.8 million euro. After adjustments for currency effects, revenue rose by 5.5 per cent. After adjustments for non-recurring effects, EBIT increased significantly by 26.7 per cent from the previous year's figure of 206.9 million euro to 262.0 million euro in 2014. This development is mainly driven by the substantial positive contribution from the reduction in pension costs in Norway and purchasing activities which improved earnings in all countries. Revenue in the Pharmacy Solutions division - the wholesale business - increased by 3.6 per cent from 17,996.0 million euro to 18,648.6 million euro. After adjustments for currency effects, revenue increased by 4.0 per cent. After adjustments for non-recurring effects, EBIT decreased by 23.3 per cent from 307.3 million euro to 235.8 million euro. On the one hand there was a favourable development in the United Kingdom, in Norway and in Austria; on the other hand challenging conditions prevailed in Germany, in Brazil, in Portugal, in France and in Belgium. Dividend for 2014 As the domination and profit and loss transfer agreement between Celesio AG and McKesson Deutschland GmbH & Co. KGaA became effective on 2 December 2014, the guaranteed dividend amounting to 0.83 euro is granted for fiscal 2014 by McKesson Deutschland. Earnings forecast In addition to cost structures, we will also continue optimizing the efficiency of our companies. However, the development of the upcoming short fiscal 2015 will be burdened by government intervention in several markets accompanied by special effects from the integration process and the ongoing challenging environment in Germany, in Brazil, in France and in Belgium. Therefore the Management Board expects revenue to increase moderately, and adjusted EBIT to be slightly below the unaudited figures for the first quarter 2014. Overall, Celesio assumes that both revenue and adjusted EBIT for fiscal 2016 will return to the level of fiscal 2014.
Key figures of the                       2013      2014       Change on EUR
Celesio Group                                                    basis in %
Continuing operations
Revenue                       EUR m  21,407.7  22,325.9                 4.3
EBITDA                        EUR m     532.8     487.4                -8.5
adjusted1)                    EUR m     548.6     532.2                -3.0
EBIT                          EUR m     406.6     237.0               -41.7
adjusted1)                    EUR m     423.6     410.9                -3.0
Net profit/loss               EUR m     171.2      52.9               -69.1
adjusted1)                    EUR m     186.4     216.6                16.2
Free cash flow                EUR m     242.8     -14.6                   /
Retail pharmacies3)                     2,175     2,184                   /
Wholesale branches3)                      133       133                   /
Discontinued operations
Net profit/loss               EUR m      -4.8      -0.5                89.6
Continuing and
discontinued operations
Net Financial Debt            EUR m  1,363.42)  867.03)               -36.4
Net Financial Debt/                    2.492)    1.633)                   /
EBITDA adj. 1) 4)
Employees3)                            38,871    38,788                   /
Net profit/loss               EUR m     166.4      52.4                   /
Earnings per share (basic)      EUR      0.94      0.25                   /


1) Adjusted for special effects from defined non-recurring expenses and income (including tax effect). 2) Closing figures as at 31 December 2013. 3) Closing figures at the end of the reporting period. 4) Based on EBITDA of the last twelve months. Press Contact Marc Binder, Celesio AG, +49 (0) 711.5001-380 [email protected] Rainer Berghausen, Celesio AG, +49 (0) 711.5001-549 [email protected] Investor Relations Michael Otto, Celesio AG, +49 (0) 711.5001-635 [email protected] Creditor Relations Marcus Hilger, Celesio AG, +49 (0) 711.5001-532 [email protected] Tobias Mommertz, Celesio AG, +49 (0) 711.5001-395 [email protected] About the Celesio Group Celesio is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care. With some 39,000 employees, Celesio operates in 14 countries around the world. Every day, the group serves over 2 million customers - at about 2,200 pharmacies of its own and over 4,300 participants in brand partnership schemes. With 133 wholesale branches, Celesio supplies 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. The services benefit a patient pool of about 15 million per day. McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson provides solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. --------------------------------------------------------------------- 17.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Celesio AG Neckartalstr. 155 70376 Stuttgart Germany Phone: +49 (0)711 5001-735 Fax: +49 (0)711 5001-740 E-mail: [email protected] Internet: www.celesio.com ISIN: DE000CLS1001 WKN: CLS100 Indices: MDAX Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Munich, Stuttgart; Regulated Unofficial Market in Hamburg, Hanover; Terminbörse EUREX End of News DGAP News-Service --------------------------------------------------------------------- 333849 17.03.2015


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 21.090,00 20.643,70 21.090,00 16.416,80 8.517,70 9.257,10 0,00
EBITDA1,2 147,50 393,90 147,50 137,10 126,30 113,50 0,00
EBITDA-Marge3 0,70 1,91 0,70 0,84 1,48 1,23 0,00
EBIT1,4 -284,60 -699,40 -284,60 2,70 -12,50 -46,30 0,00
EBIT-Marge5 -1,35 -3,39 -1,35 0,02 -0,15 -0,50 0,00
Jahresüberschuss1 -299,00 -966,00 -295,30 -54,60 -7,30 -867,40 0,00
Netto-Marge6 -1,42 -4,68 -1,40 -0,33 -0,09 -9,37 0,00
Cashflow1,7 265,90 422,30 265,90 345,00 362,50 0,90 0,00
Ergebnis je Aktie8 -1,49 -3,97 -1,47 -0,29 -1,22 -4,29 0,64
Dividende8 0,83 0,83 0,83 0,83 0,83 0,83 0,83
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
McKesson Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
CLS100 20,700 Halten 4.206,67
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
25,88 22,33 1,17 -24,38
KBV KCV KUV EV/EBITDA
1,69 4.674,08 0,45 20,95
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,83 0,83 4,01 29.07.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.06.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
1,71% -4,42% -13,75% -13,75%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Celesio AG  ISIN: DE000CLS1001 können Sie bei EQS abrufen


Handel , CLS100 , CLS1 , SWB:​MCK